A5069819572- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Surgical Treatments
- Monoclonal and Polyclonal Antibodies Research
- Gastrointestinal Tumor Research and Treatment
- Chronic Lymphocytic Leukemia Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Prostate Cancer Treatment and Research
- PI3K/AKT/mTOR signaling in cancer
- Immune Cell Function and Interaction
- Radiomics and Machine Learning in Medical Imaging
- Glycosylation and Glycoproteins Research
- Colorectal and Anal Carcinomas
- Advanced Breast Cancer Therapies
Ospedale San Giovanni Bellinzona
2008-2025
Università della Svizzera italiana
2019-2025
Ente Ospedaliero Cantonale
2022-2025
Institute of Oncology Research
2012-2023
Ospedale regionale di Lugano
2023
ORCID
2021
Ospedale Regionale di Bellinzona e Valli
2018
University of Bern
2013
Fondazione IRCCS Istituto Nazionale dei Tumori
2004-2012
Tel Aviv Sourasky Medical Center
2012
PURPOSE Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% 40% patients who not responsive. The serine-threonine kinase BRAF is the principal effector of KRAS. We hypothesized that, wild-type patients, could have a predictive/prognostic value. PATIENTS AND METHODS retrospectively analyzed objective tumor responses, time progression, overall survival (OS), and mutational status 113 tumors...
Abstract Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5 . Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification patients optimal response to therapy unmet need 6,7 Here we report the progressive accumulation exhausted, unconventionally activated CD8 + PD1 T cells in NASH-affected livers. In preclinical models NASH-induced therapeutic immunotherapy targeted at programmed...
The monoclonal antibodies (moAb) panitumumab and cetuximab target the epidermal growth factor receptor (EGFR) have proven valuable for treatment of metastatic colorectal cancer (mCRC). EGFR-mediated signaling involves two main intracellular cascades: on one side KRAS activates BRAF, which in turn triggers mitogen-activated protein kinases. On other, membrane localization lipid kinase PIK3CA counteracts PTEN promotes AKT1 phosphorylation, thereby activating a parallel axis. Constitutive...
•Baseline serum AFP ≥100 ng/ml and CRP ≥1 mg/dl were independently associated with worse OS in ICB-treated patients HCC.•A score based on these two variables predicts disease control rate overall survival HCC.•The was validated an independent cohort of HCC.•In sorafenib-treated HCC, the prognostic for but not predictive rate. Background & AimsImmunotherapy atezolizumab plus bevacizumab represents new standard care systemic front-line treatment hepatocellular carcinoma (HCC). However,...
Background KRAS mutations occur in 35–45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type tumors achieve objective response. Alterations other effectors downstream the EGFR, such as BRAF, deregulation PIK3CA/PTEN pathway have independently been found give rise resistance. We present a comprehensive analysis KRAS, PIK3CA mutations, PTEN expression mCRC treated...
KRAS mutations represent the main cause of resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) in metastatic colorectal cancer (mCRC). We evaluated whether highly sensitive methods for investigation improve accuracy predictions anti-EGFR MoAbs efficacy.We retrospectively objective tumor responses mCRC patients treated with cetuximab or panitumumab. codons 12 and 13 were examined by direct sequencing, MALDI-TOF MS, mutant-enriched PCR, engineered which...
In metastatic colorectal cancer (mCRC), KRAS is the only validated biomarker used to select patients for administration of epidermal growth factor receptor (EGFR)-targeted therapies. To identify additional predictive markers, we investigated importance HER2, primary EGFR dimerisation partner, in this particular disease. We evaluated HER2 gene status by fluorescence situ hybridisation (FISH) 170 wild-type mCRC treated with cetuximab or panitumumab. Depending on copy number status, showed...
Cetuximab and panitumumab efficacy in metastatic colorectal cancer (mCRC) may be influenced by EGFR gene status and/or deregulation of its downstream signalling proteins detected primary tumour. However, metastasis might have different molecular patterns with respect to tumour, possibly affecting the prediction EGFR-targeted therapy efficacy. We analysed tumour 38 mCRC patients. Twelve cases were cetuximab/panitumumab treated. protein expression investigated through fluorescent situ...
Journal of Cancer Metastasis and Treatment is an open access journal, focusing on basic clinical studies related to cancer cell, cell biology, oncology, radiation therapy radiology, obstetrics gynecology, pediatrics, surgery, hematology, neuro-oncology, etc.
Locally advanced rectal cancer (LARC) is treated with neoadjuvant chemo-radiotherapy (nCRT) followed by surgery. A minority of patients show complete response (CR) to nCRT and may avoid surgery its functional consequences. Instead, most non-complete (non-CR) benefit from additional treatments increase CR rates. Reliable predictive markers are lacking. Aim this study was identify novel signatures predicting responsiveness. We performed a combined analysis tumor-associated microbiome immune...
We assessed the benefit of adjuvant aspirin in resected PIK3CA-mutated colon cancer patients. This was a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, and multinational trial. Patients with stage II III harbouring an activating PIK3CA mutation were included. Due to financial constraints, trial prematurely closed. Randomization 2:1 100mg versus placebo daily for 3 years. The primary endpoint disease-free survival (DFS). Secondary endpoints included time...
Abstract BACKGROUND. The noninferiority of a 6‐week dosing schedule lanreotide Autogel (Lan ATG) at dose 120 mg compared with 3‐week microparticles MP) 60 was investigated in patients neuroendocrine tumors (NET). METHODS. Patients who had sporadic, well differentiated NET low grade malignancy were recruited for this open‐label, Phase III, multicenter trial. randomized to receive either 3 deep subcutaneous injections Lan ATG (120 mg, every 6 weeks) or intramuscular MP (60 weeks). Tumor...
Combined chemoradiation therapy is the gold standard in treatment of squamous cell anal cancer (SCAC). However, even if response rate very high, many patients eventually relapse or experience a reccurrence, thus requiring an invasive surgical procedure that has severe side effects. Most SCAC tumors overexpress epidermal growth factor receptor (EGFR); therefore, it reasonable to consider anti-EGFR drugs as new option, demonstrated by anecdotal reports. Promising results obtained other solid...